Thermo Fisher's 'Outstanding Quarter' Confirms the Biotech Recovery Is for Real
Organic growth accelerates to 5% as pharma/biotech strength broadens; company raises guidance and deploys $1B buyback ahead of microbiology divestiture.
TMO · Earnings Call · 2026-07-23
A Broad-Based Acceleration
Thermo Fisher's second-quarter report was a clean beat on both top and bottom lines, and the tone from management was unmistakably confident. “Customer activity across our end markets continue to strengthen.” — Marc Casper, Chairman and Chief Executive Officer · 2026-07-23 That wasn't hyperbole: organic growth stepped up to 5% from 3% in Q1, with revenue of $11.99 billion (+10% reported, +5% organic) and adjusted EPS of $6.03 (+13%). The Customer activity keyword, which ranked #1 in the company's latest keyword trajectory, captures the core narrative: the long-awaited recovery in biotech funding is finally translating into orders and revenue. Marc Casper noted, “We've talked a lot about how activity has been picking up, but now it's good to see that's translating into the revenue as well.” — Marc Casper, Chairman and Chief Executive Officer · 2026-07-23 All four end markets posted mid-single-digit or better growth, with Pharma and Biotech (60% of revenue) leading. Academic and Government returned to low-single-digit growth, a notable reversal from the flat-to-declining trend of the past year—though management remains cautious about calling a new trend after just one quarter. The Pharma Biotech keyword captures the momentum, and the company's “proven growth strategy” is resonating, as evidenced by the academic research keyword rising in the trajectory.Innovation and End-Market Recovery
A standout was Analytical Instruments, which grew 7% organically—its best performance in recent quarters—driven by all three businesses. The easy comparison from last year's tariff disruption helped, but the real driver was innovation. Marc highlighted the launch of two Orbitrap mass spectrometers and AI-enabled software at ASMS: “We saw strong adoption of our high-end instrumentation broadly and especially actually globally in the academic customer set.” — Marc Casper, Chairman and Chief Executive Officer · 2026-07-23 The Mass Spectrometry keyword (ranked #7 this quarter) is clearly a core differentiator. The company's scientific discovery keyword also surfaces in this context, as the new platforms enable novel research. Bioproduction delivered another “excellent” quarter, with growth comfortably ahead of peers. Management explicitly addressed a competitor's customer delays—TMO hasn't seen them. In clinical research, PPD saw strong authorizations and revenue growth, and the Clario acquisition is contributing well. The acquisition of Clario keyword (ranked #1 in Q2) is now a major contributor, adding to the contribution from acquisition theme.Portfolio Management and Capital Return
The quarter was also notable for active portfolio management. Thermo signed an agreement to divest the microbiology business (closing Q3) and repurchased $1 billion of shares in Q2 using the anticipated net proceeds. The pending divestiture keyword is new and ranks #16, reflecting the strategic pivot. Combined with the earlier $3 billion buyback, the company is returning substantial capital while maintaining flexibility for M&A.This disciplined approach is consistent with management's stated priority: strategic M&A complemented by shareholder returns. From a fundamental perspective, the quarter's operating leverage is clear: adjusted operating income grew 15% on 10% revenue growth, and adjusted operating margin expanded 90 basis points to 22.8%. Operating margin of 16.9% (GAAP) reflects the strong cash conversion and productivity gains. The company's free cash flow remains robust (year-to-date $2.5 billion), supporting the buyback.We deployed the anticipated net proceeds from this transaction to repurchase $1 billion of our shares in the second quarter.